| Name | Title | Contact Details |
|---|
Formycon ist ein führender und unabhängiger Entwickler von qualitativ hochwertigen biopharmazeutischen Nachfolgeprodukten, sogenannten Biosimilars.
We focus on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use.
RareCyte is a company focused on characterizing and isolating rare cells from blood.
Sentien Biotechnologies, Inc. is a privately owned, clinical stage company developing novel approaches to cell therapy. Our lead product is designed to allow for controlled, sustained delivery of mesenchymal stem cell (MSC) secreted factors. This approach immobilizes the MSCs in an extracorporeal device, allowing for doses of therapeutic secreted factors that are unattainable by direct injection.
Kirin Pharma USA is a La Jolla, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.